BSE Live
Jan 15, 15:59Prev. Close
3.97
Open Price
4.06
Bid Price (Qty.)
4.11 (2390)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 11, 15:18Prev. Close
4.15
Open Price
4.40
Bid Price (Qty.)
4.20 (500)
Offer Price (Qty.)
4.25 (2249)
| Cash Flow of Jupiter Bioscience (in Rs. Cr.) | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 58.28 | 49.07 | 37.75 | 34.46 | 27.06 | |
| Net CashFlow From Operating Activities | 117.54 | 92.11 | 68.12 | 47.77 | 17.76 | |
| Net Cash Used In Investing Activities | -514.40 | -220.15 | -143.19 | -163.21 | -104.69 | |
| Net Cash Used From Financing Activities | 394.71 | 132.92 | 74.26 | 115.35 | 87.99 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -2.15 | 4.87 | -0.81 | -0.09 | 1.06 | |
| Cash And Cash Equivalents Begin of Year | 6.44 | 1.57 | 2.39 | 2.48 | 1.42 | |
| Cash And Cash Equivalents End Of Year | 4.29 | 6.44 | 1.57 | 2.39 | 2.48 |
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth